EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Use of glucagon‐like peptide‐1 receptor agonists in eating disorder populations

Sara Bartel iD, Susan L McElroy iD, Danielle Levangie iD, Aaron Keshen iD

International Journal of Eating Disorders · 2024-02 · 57 (2) · 286-293

DOI: 10.1002/eat.24109 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Eating Disorders, online erschienen am 22.12.2023. Verfasst von Sara Bartel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Eating Disorder Provincial Service, Nova Scotia Health, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: Binge-Eating Disorder. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon‐like peptide‐1 receptor agonists (GLP‐1As) are being used as approved or off‐label treatments for weight loss. As such, there has been increasing concern about the potential for GLP‐1As to impact eating disorder (ED) symptomatology. This article seeks to (1) review the current state of knowledge regarding GLP‐1As and ED symptomatology; (2) provide recommendations for future research; and (3) guide ED clinicians in how to discuss GLP‐1As in clinical practice. Although evidence is limited, it is possible that GLP‐1As could exacerbate, or contribute to the development of, ED pathology and negatively impact ED treatment. Preliminary research on the use of GLP‐1As to treat binge eating has been conducted; however, studies have design limitations and additional research is needed. Therefore, at the current time there is not sufficient evidence to support the use of GLP‐1s to treat ED symptoms. In summary, more research is required before negative or positive conclusions can be drawn about the impact of GLP‐1As on EDs psychopathology. Herein, we provide specific recommendations for future research and a guide to help clinicians navigate discussions with their clients about GLP‐1As. A client handout is also provided. Public Significance Despite glucagon‐like peptide‐1 receptor agonists (GLP‐1As; e.g., semaglutide) increasingly being the topic of clinical and public discourse, little is known about their potential impact on ED symptoms. It is possible that GLP‐1As could maintain, worsen, or improve ED symptoms. This article reviews the limited literature on GLP‐1As and ED symptoms, recommends future research, and provides clinicians with a guide for discussing GLP‐1As with ED clients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Binge-Eating DisorderHumansGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Stichwörter der Autor:innen

GLP-1 receptor agonistsOzempic™binge eatingeating disorderssemaglutide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Eating Disorder Provincial Service, Nova Scotia Health, Halifax, Nova Scotia, Canada.
  • Lindner Center of HOPE, Mason, Ohio, USA.
  • Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.

ORCID-Profile: Sara Bartel, Susan L McElroy, Danielle Levangie, Aaron Keshen

Zitieren

APA

Bartel, S., McElroy, S. L., Levangie, D., & Keshen, A. (2024). Use of glucagon‐like peptide‐1 receptor agonists in eating disorder populations. International Journal of Eating Disorders, 57(2), 286-293. https://doi.org/10.1002/eat.24109

Vancouver

Bartel S, McElroy SL, Levangie D, Keshen A. Use of glucagon‐like peptide‐1 receptor agonists in eating disorder populations. International Journal of Eating Disorders. 2024;57(2):286-293. doi:10.1002/eat.24109

BibTeX
@article{Bartel2024,
  author = {Bartel, Sara and McElroy, Susan L and Levangie, Danielle and Keshen, Aaron},
  title = {Use of glucagon‐like peptide‐1 receptor agonists in eating disorder populations},
  journal = {International Journal of Eating Disorders},
  year = {2024},
  volume = {57},
  number = {2},
  pages = {286--293},
  doi = {10.1002/eat.24109}
}
Kostenlos starten →